Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Biocatalysis. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN120718880B reveals high-efficiency transaminase mutant for Cinacalcet intermediate synthesis offering significant cost and supply chain advantages.
Patent CN114507650A details a high-efficiency biocatalytic route for Clopidogrel intermediates, offering superior stereoselectivity and substrate tolerance for scalable API manufacturing.
Patent CN108486075A details a mutant enzyme for statin side chains, offering enhanced catalytic efficiency and cost reduction in pharmaceutical intermediate manufacturing.
Patent CN118480524B details mutant enzyme synthesis for chloramphenicol intermediates. Delivers high yield and green manufacturing advantages for reliable pharmaceutical intermediates supplier partnerships.
Patent CN116179503A details a novel recombinant aminotransferase route for Niraparib intermediates, offering high stereoselectivity and eliminating costly chiral chromatography for supply chain efficiency.
Patent CN115851685A reveals a breakthrough nitrilase mutant for efficient 3-hydroxy-3-methylbutyric acid production, offering significant cost reduction and green manufacturing advantages.
Patent CN104561142A reveals nitrilase biosynthesis for statin intermediates. Offers mild conditions, high yield, and supply chain stability for global pharmaceutical manufacturing.
Patent CN114150009A reveals a novel enzymatic route for ephedrine using engineered E. coli and yeast, offering high yield and environmental compliance for pharma supply chains.
Patent CN114958934A reveals a novel glutamate dehydrogenase method for L-glufosinate. Achieve high purity and cost reduction in agrochemical intermediate manufacturing.
High-yield imine reductase method for ephedrine production offers supply chain stability and cost efficiency for pharmaceutical intermediates.
Patent CN110951706B details a high-activity R-omega-TA mutant for sitagliptin. Offers high ee value >99%, breaking technical monopolies and ensuring supply chain stability.
Patent CN110577941A reveals mutated amine dehydrogenase for asymmetric reductive amination. Enables cost reduction in pharmaceutical intermediates manufacturing with high optical purity.
Patent CN111100851B discloses high-efficiency TbSADH mutants for synthesizing chiral biaryl alcohols with >99% ee, offering a green alternative to metal catalysis.
Novel TbSADH mutants enable high-yield synthesis of chiral biaryl alcohols. Efficient biocatalysis for pharmaceutical intermediates with superior stereoselectivity.
Patent CN114736882B reveals high-efficiency biocatalysis for antiviral intermediates. Offers supply chain stability and cost reduction in API manufacturing without heavy metals.
Novel aminotransferase mutants enable high-yield sitagliptin synthesis. Cost-effective, scalable pharma intermediate solution with >99% ee.
Novel transaminase mutant enables high-yield sitagliptin intermediate synthesis with superior stereoselectivity and scalable biocatalytic process efficiency for global supply.
Patent CN107889505B reveals a novel enzymatic route for NMN production, eliminating expensive PRPP substrates to ensure cost-effective and scalable supply chain solutions.
Patent CN111057729B reveals enzymatic synthesis for high-purity Larotrectinib intermediates. Discover cost-effective, scalable biocatalytic manufacturing solutions.
Patent CN117701523A reveals solvent-tolerant transaminase for high-purity sitagliptin intermediate manufacturing with significant supply chain cost reduction.